Welcome to our dedicated page for Heartflow news (Ticker: HTFL), a resource for investors and traders seeking the latest updates and insights on Heartflow stock.
Heartflow, Inc. develops AI-enabled software for non-invasive detection and management of coronary artery disease. Its updates center on the Heartflow Platform and related analyses, including Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow Roadmap Analysis, which use coronary CT imaging and software-based interpretation to support cardiovascular care.
Recurring news includes quarterly results, account adoption, payer coverage and reimbursement for Plaque Analysis, clinical evidence presented at cardiology meetings, patient registries such as GAMEFILM and NAVIGATE-PCI, investor conference activity, intellectual property enforcement and additions to Heartflow’s product platform such as PCI Navigator.
Heartflow (Nasdaq: HTFL) announced management will participate in a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on March 3, 2026.
The presentation is scheduled for 10:45 a.m. PT / 1:45 p.m. ET, with a live webcast and archived replay available via the company's Investor Relations website.
Heartflow (Nasdaq: HTFL) will report fourth quarter and full year 2025 financial results after market close on March 18, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live webcast and archived replay available for 12 months.
Investors must register to receive dial-in numbers and a unique PIN; participants are encouraged to register at least 15 minutes before the call.
Heartflow (Nasdaq: HTFL) announced expansion of its GAMEFILM Registry on February 12, 2026 to include former NBA and NHL players, building on an initial phase with NFL alumni.
The non-invasive registry uses AI-powered Heartflow Plaque Analysis with CCTA across 15 U.S. sites, has enrolled over 140 retired athletes and aims for up to 300 participants to study coronary plaque and risk.
Heartflow (Nasdaq: HTFL) announced that Aetna now covers Heartflow Plaque Analysis across Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans, effective December 23, 2025 for patients with acute or stable chest pain and 1–69% coronary stenosis on coronary CTA. This makes Aetna the fourth major national payer to align coverage with EviCore and expands access to the majority of insured lives in the U.S.
Reimbursement moved forward with new Category I CPT code 75577 effective January 1, 2026, establishing 0.85 RVUs for physicians and a combined total of 4.00 RVUs. The release cites real-world evidence including the DECIDE Registry (>50% management change) and FDA clearance with 95% agreement to IVUS.
Heartflow (Nasdaq: HTFL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available on Heartflow's Investor Relations website at https://ir.heartflow.com.
The presentation will cover recent company developments and outlook for investors; timing and access details are provided for shareholders and analysts.
Heartflow (Nasdaq: HTFL) announced that the American College of Cardiology and American Heart Association published scientific statements endorsing the prognostic value of quantitative coronary plaque assessment and highlighting the coronary CTA + Heartflow pathway for personalized CAD management on Dec 18, 2025.
Heartflow said its Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with 95% agreement to IVUS using blinded core-lab adjudication. The company cited real-world evidence including the DECIDE registry, where Plaque Analysis changed medical management in more than 50% of patients, and a FISH&CHIPS cohort validation presented at AHA 2025.
Heartflow (Nasdaq: HTFL) announced two large real-world analyses from FISH&CHIPS (England NHS) covering >90,000 patients, presented at EACVI on Dec 11, 2025. The reports show lesion-specific FFRCT predicts individual outcomes: patients with the lowest FFRCT had a 4× higher MI risk and 3× higher cardiovascular death risk, independent of traditional risk factors. A separate health‑economic analysis found £1,042 GBP ($1,394 USD) per‑patient savings at two years, with modeled system savings of about £25 million GBP ($33.45 million USD) per year and reduced downstream testing and increased appropriate revascularization.
Findings support clinical and economic value of the Heartflow One platform and lesion-specific FFRCT in large health systems.
Heartflow (Nasdaq: HTFL) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 p.m. PT / 3:30 p.m. ET. The session will be available live and archived on the company's Investor Relations website.
Investors can access the webcast and archived replay at https://ir.heartflow.com.
Heartflow (Nasdaq: HTFL) reported third quarter 2025 results on November 12, 2025, with total revenue of $46.3 million, up 41% YoY, and gross margin of 76.5%. The company posted a net loss of $50.9 million (loss per share $1.04), which included a $32.1 million noncash warrant remeasurement charge and a $6.4 million loss on extinguishment of debt. Heartflow completed an IPO in August 2025, raising approximately $364.2 million, and had $291.2 million in cash and equivalents as of September 30, 2025.
The company initiated full-year 2025 revenue guidance of $173.0 million to $173.5 million (≈37.5%–38.0% growth). Operational highlights include broad commercial payor coverage for Heartflow Plaque Analysis and DECIDE registry findings showing medical management change in over half of patients versus CCTA alone.
Heartflow (Nasdaq: HTFL) reported late-breaking FISH&CHIPS results at AHA 2025 showing AI-driven Heartflow Plaque Analysis total plaque volume (TPV) staging predicts long-term coronary risk.
Key data: a retrospective cohort of nearly 8,000 symptomatic patients; highest TPV stage had a hazard ratio 5.10 (p < 0.0001) for major cardiovascular events over a median 3.3 years. Associations remained after adjustment for stenosis, FFRCT and risk factors. Related DECIDE registry data showed medical-management changes with an average LDL reduction of 18.7 mg/dL at 90 days and an expected 15% decrease in cardiac event risk. Plaque Staging is investigational-only; Heartflow Plaque Analysis is FDA-cleared.